Tesamorelin and HIV lipodystrophy — the only approved GHRH analog
In the early 2000s it became clear that combination antiretroviral therapy in HIV-positive patients causes a peculiar body-fat redistribution — visceral adiposity alongside peripheral lipoatrophy. In 2010 tesamorelin, a stabilised GHRH analog from the Canadian firm Theratechnologies, received FDA approval for exactly this indication. To this day the only GHRH analog with an ICH-GCP-compliant human approval.
An unusual indication
From the mid-1990s — with the breakthrough of highly active antiretroviral therapy (HAART) — clinicians observed a new body-fat redistribution in HIV-positive patients: increased visceral abdominal fat, alongside loss of subcutaneous fat in arms, legs and cheeks. This syndrome — today called HIV-associated lipodystrophy — is a direct consequence of several antiretroviral substance classes, particularly earlier protease inhibitors and thymidine analogs. Clinically relevant are the cardiovascular co-signals: elevated triglycerides, insulin resistance, unfavourable cholesterol profiles.
Until the mid-2000s, no pharmacological therapy specifically addressed the visceral component. Diet and exercise helped to a limited extent; recombinant growth hormone had the right metabolic profile but at the necessary doses was associated with insulin resistance and glucose intolerance. The question was: can the GHRH pathway be pharmacologically activated more gently?
The substance: stabilised GHRH(1-44)
Tesamorelin (TH9507) is a modified form of human GHRH(1-44) with a trans-3-hexenoyl modification at the N-terminus that extends plasma half-life and increases resistance to dipeptidyl peptidase-IV. The substance was developed in the late 1990s at Theratechnologies in Montréal. Unlike recombinant growth hormone, tesamorelin stimulates pituitary GH secretion and thereby preserves the physiological pulsatile secretion structure — which theoretically yields a more favourable metabolic profile than continuous supraphysiological substitution.
Clinical development began in 2003-2004 with phase 2 trials in HIV lipodystrophy. Endpoints were structural-anthropometric: reduction of visceral adiposity measured by CT/MRI, plus safety and metabolic parameters.
The pivotal phase 3 trials
Two pivotal phase 3 trials — both multinational, randomised, placebo-controlled, with over 800 participants in total — were completed 2007-2009 and published 2010 in NEJM and JCEM (Grinspoon S et al.). Result: tesamorelin 2 mg s.c. daily reduced visceral adiposity (measured by CT) over 26 weeks by about 15-18% versus placebo. Triglycerides decreased significantly; glucose homeostasis remained stable in the majority of patients.
On the basis of these data, the FDA granted approval in November 2010 — under the name Egrifta. It was the first and remains to this day the only indication of a GHRH analog with FDA approval. Tesamorelin is available in US HIV care as an add-on therapy in lipodystrophic visceral adiposity.
„The substance does something recombinant growth hormone cannot: it activates the endogenous control loop instead of overwriting it. That makes the metabolic profile more favourable."
What is clear about broader use — and what is not
Tesamorelin is exclusively approved for HIV-associated lipodystrophy. In this indication, the evidence base is solid. Off-label uses — visceral adiposity in non-HIV patients, anti-aging, body-composition optimisation in sport — are not supported by approval-relevant trials. A series of smaller academic studies has investigated tesamorelin in NAFLD/NASH (non-alcoholic fatty liver disease) and cognitive function in geriatrics; results are interesting but not approval-ready.
As with all GHRH analogs: prolonged growth-hormone elevation is associated with potential oncological risks, especially with pre-existing malignant disease. In the HIV trials no increased malignancy rates were observed, but trial duration (26-52 weeks) is too short for such endpoints.
Economic reality and black market
Egrifta is high-priced in the US — therapy typically costs several thousand dollars per month. This price structure combined with the narrowly defined indication has made the substance attractive in anti-aging and bodybuilding black markets from the 2010s onwards. Tesamorelin is positioned in these markets as a 'cleaner alternative to rHGH' — with the argument that endogenous pulsation is preserved and insulin effects are more favourable. These arguments have mechanistic plausibility but are not supported by approval-relevant data outside the HIV indication.
Open questions
- Which tesamorelin trials in NAFLD/NASH reach phase 3 standards?
- Can the indication be extended to other lipodystrophy forms — congenital lipodystrophies, Cushing's syndrome sequelae?
- What long-term data (>5 years) on malignancy rates under tesamorelin exist?
- How does the price structure change global access — particularly in HIV-endemic regions where lipodystrophy is common?